Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diabetes
Research on diabetes discussed by scientists at University of Pittsburgh, Medical Department
July 30th, 2008
According to recent research published in the journal Diabetes, "This study was aimed at ascertaining the efficacy of antisense oligonucleotide-formulated microspheres to prevent type 1 diabetes and to reverse new-onset disease. Microspheres carrying antisense oligonucleotides to CD40, CD80, and CD86 were delivered into NOD mice." "Glycemia was monitored to determine disease prevention and reversal. In recipients that remained and/or became diabetes free, spleen and lymph node T-cells were enriched to determine the prevalence of Foxp3(+) putative regulatory T-cells (Treg cells). Splenocytes from diabetes-free microsphere-treated recipients were adoptively...
Source: Vaccine Weekly (2008-07-30)
|
